Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAXCYTE, INC.MXCT · Entity 6608 | Director · President and CEO | December 04, 2023 | December 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAXCYTE, INC.
Report date December 04, 2023 · Filed December 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 333,197 |
Ending reported balance
After 2023-12-05 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-12-04 · Exercise / conversion · Acquired 25,008 · Balance 358,205 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Row 2 · 2023-12-04 · Sale · Disposed 25,008 · Balance 333,197 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F2: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2023-12-05 · Exercise / conversion · Acquired 99,442 · Balance 432,639 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Row 4 · 2023-12-05 · Sale · Disposed 99,442 · Balance 333,197 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F3: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2024-11-11 | Direct | 184,522 |
Reported balance
After 2023-12-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-12-04 · Exercise / conversion · Disposed 25,008 · Balance 184,522 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4: This option is fully vested and exercisable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2024-11-11 | Direct | 85,080 |
Reported balance
After 2023-12-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-12-05 · Exercise / conversion · Disposed 99,442 · Balance 85,080 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4: This option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024.
F2: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: This option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2023 Filed Apr 4, 2023 18:59 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 100 | $0.04 | $4.00 |
DisclosureSEC source: 0001209191-23-022983 · doc4.xml · nonDerivative · entry 3 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 18:59 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,607 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-022983 · doc4.xml · derivative · entry 7 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 382,473 Underlying: Common Stock · 2,607 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 18:59 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 2,607 | $5.00 | $13,035.00 |
DisclosureSEC source: 0001209191-23-022983 · doc4.xml · nonDerivative · entry 2 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 18:59 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 2,607 | $0.04 | $104.28 |
DisclosureSEC source: 0001209191-23-022983 · doc4.xml · nonDerivative · entry 1 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 335,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 16:42 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0001209191-23-020285 · doc4.xml · derivative · entry 1 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-03-19 F1 · derivative.exercise_date: 25% of the shares underlying this option vest on March 20, 2024 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 16:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,665 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-006876 · doc4.xml · derivative · entry 6 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,080 Underlying: Common Stock · 10,665 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 16:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 10,665 | $5.77 | $61,537.05 |
DisclosureSEC source: 0001209191-23-006876 · doc4.xml · nonDerivative · entry 4 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.69 to $5.885, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 16:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 10,665 | $0.04 | $426.60 |
DisclosureSEC source: 0001209191-23-006876 · doc4.xml · nonDerivative · entry 3 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 19,335 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-006876 · doc4.xml · derivative · entry 5 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,745 Underlying: Common Stock · 19,335 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 19,335 | $5.69 | $110,016.15 |
DisclosureSEC source: 0001209191-23-006876 · doc4.xml · nonDerivative · entry 2 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.50 to $5.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 19,335 | $0.04 | $773.40 |
DisclosureSEC source: 0001209191-23-006876 · doc4.xml · nonDerivative · entry 1 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 17:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,234 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-001995 · doc4.xml · derivative · entry 9 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,080 Underlying: Common Stock · 10,234 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 17:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 10,234 | $5.04 | $51,579.36 |
DisclosureSEC source: 0001209191-23-001995 · doc4.xml · nonDerivative · entry 6 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 17:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 10,234 | $0.04 | $409.36 |
DisclosureSEC source: 0001209191-23-001995 · doc4.xml · nonDerivative · entry 5 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 17:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,153 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-001995 · doc4.xml · derivative · entry 8 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,314 Underlying: Common Stock · 9,153 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 17:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 9,153 | $5.07 | $46,405.71 |
DisclosureSEC source: 0001209191-23-001995 · doc4.xml · nonDerivative · entry 4 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.19, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 17:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 9,153 | $0.04 | $366.12 |
DisclosureSEC source: 0001209191-23-001995 · doc4.xml · nonDerivative · entry 3 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 17:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,613 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-23-001995 · doc4.xml · derivative · entry 7 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,467 Underlying: Common Stock · 10,613 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 17:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 10,613 | $5.13 | $54,444.69 |
DisclosureSEC source: 0001209191-23-001995 · doc4.xml · nonDerivative · entry 2 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,197 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.49, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 17:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 10,613 | $0.04 | $424.52 |
DisclosureSEC source: 0001209191-23-001995 · doc4.xml · nonDerivative · entry 1 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 16:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-22-021460 · doc4.xml · derivative · entry 1 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2032-03-24 F1 · derivative.exercise_date: 25% of the shares underlying this option vest on March 25, 2023 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 19:08 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 74,890 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-064875 · doc4.xml · derivative · entry 9 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,080 Underlying: Common Stock · 74,890 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 19:08 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 74,890 | $12.08 | $904,671.20 |
DisclosureSEC source: 0001209191-21-064875 · doc4.xml · nonDerivative · entry 6 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,197 F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 19:08 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 74,890 | $0.04 | $2,995.60 |
DisclosureSEC source: 0001209191-21-064875 · doc4.xml · nonDerivative · entry 5 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 19:08 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 123,263 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-064875 · doc4.xml · derivative · entry 8 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 519,970 Underlying: Common Stock · 123,263 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 19:08 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 123,263 | $12.16 | $1,498,878.08 |
DisclosureSEC source: 0001209191-21-064875 · doc4.xml · nonDerivative · entry 4 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,197 F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.03 to $12.615, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 19:08 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 123,263 | $0.04 | $4,930.52 |
DisclosureSEC source: 0001209191-21-064875 · doc4.xml · nonDerivative · entry 3 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 19:08 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,847 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-064875 · doc4.xml · derivative · entry 7 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,233 Underlying: Common Stock · 1,847 shares Expires 2024-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 19:08 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 101,847 | $12.66 | $1,289,383.02 |
DisclosureSEC source: 0001209191-21-064875 · doc4.xml · nonDerivative · entry 2 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,197 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.56 to $12.765, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 19:08 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 1,847 | $0.04 | $73.88 |
DisclosureSEC source: 0001209191-21-064875 · doc4.xml · nonDerivative · entry 1 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 17:11 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.63 | $0.00 |
DisclosureSEC source: 0001209191-21-050928 · doc4.xml · derivative · entry 1 Doerfler Douglas · CIK 0001874482 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-08-09 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on August 9, 2022 and the remaining shares underlying the option vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.